Abstract
Gynecologic cancer is a major burden in both developed and developing countries. Almost a half million deaths from gynecologic cancer are reported each year. Understanding the molecular biology of cancer is a principle resource leading to the identification of new potential therapeutic targets, which may be parlayed into novel therapeutic options in gynecologic cancer. Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase, which plays a pivotal role in many aspects of malignant growth including cancer cell survival, migration, invasion, angiogenesis and metastasis. Various human cancer tissues have demonstrated high expression of FAK or activated FAK, which has been correlated with survival of cancer patients. Among gynecologic cancers, reports have emerged demonstrating that FAK is involved in the pathogenesis of ovarian, endometrial, and cervical cancers. In addition, the polycomb group protein enhancer of Zeste homologue 2 (EZH2), Dll4/notch and EphA2 has also emerged as important regulators of endothelial cell biology and angiogenesis. Herein, we review the role of these new targets in tumor angiogenesis and the rationale for further clinical development.
Keywords: Focal adhesion kinase, EZH2, Dll4/notch, ovarian cancer, uterine cancer, cervix cancer, angiogenesis, endothelial cells, gynecologic cancer, polycomb group protein
Current Pharmaceutical Design
Title:Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer
Volume: 18 Issue: 19
Author(s): Duangmani Thanapprapasr, Wei Hu, Anil K Sood and Robert L Coleman
Affiliation:
Keywords: Focal adhesion kinase, EZH2, Dll4/notch, ovarian cancer, uterine cancer, cervix cancer, angiogenesis, endothelial cells, gynecologic cancer, polycomb group protein
Abstract: Gynecologic cancer is a major burden in both developed and developing countries. Almost a half million deaths from gynecologic cancer are reported each year. Understanding the molecular biology of cancer is a principle resource leading to the identification of new potential therapeutic targets, which may be parlayed into novel therapeutic options in gynecologic cancer. Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase, which plays a pivotal role in many aspects of malignant growth including cancer cell survival, migration, invasion, angiogenesis and metastasis. Various human cancer tissues have demonstrated high expression of FAK or activated FAK, which has been correlated with survival of cancer patients. Among gynecologic cancers, reports have emerged demonstrating that FAK is involved in the pathogenesis of ovarian, endometrial, and cervical cancers. In addition, the polycomb group protein enhancer of Zeste homologue 2 (EZH2), Dll4/notch and EphA2 has also emerged as important regulators of endothelial cell biology and angiogenesis. Herein, we review the role of these new targets in tumor angiogenesis and the rationale for further clinical development.
Export Options
About this article
Cite this article as:
Thanapprapasr Duangmani, Hu Wei, K Sood Anil and L Coleman Robert, Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer, Current Pharmaceutical Design 2012; 18 (19) . https://dx.doi.org/10.2174/138161212800626201
DOI https://dx.doi.org/10.2174/138161212800626201 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cellular Targets and Mechanisms in the Cytotoxic Action of Non-biodegradable Engineered Nanoparticles
Current Drug Metabolism Particle Sorting in Microfluidic Systems
Micro and Nanosystems LPS/TLR4 Pathways in Breast Cancer: Insights into Cell Signalling
Current Medicinal Chemistry Novel Implications for Lysophospholipids, Lysophosphatidic Acid and Sphingosine 1-Phosphate, as Drug Targets in Cancer
Anti-Cancer Agents in Medicinal Chemistry Control of Tumor Markers Using Nanotechnology
Mini-Reviews in Medicinal Chemistry Pharmacological Potentials and Nutritional Values of Tropical and Subtropical Fruits of India: Emphasis on their Anticancer Bioactive Components
Recent Patents on Anti-Cancer Drug Discovery Transforming Growth Factor β Signaling Perturbation in the Loeys-Dietz Syndrome
Current Medicinal Chemistry The Role of the Healthy Dietary Intake in Women with Human Papilloma Virus
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Targeted Regulation of PI3K/Akt/mTOR/NF-κB Signaling by Indole Compounds and their Derivatives: Mechanistic Details and Biological Implications for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Impact of Curcumin on Microsomal Enzyme Activities: Drug Interaction and Chemopreventive Studies
Current Medicinal Chemistry Genetic Markers of Osteoarthritis
Current Rheumatology Reviews Opportunities and Challenges in Nano-structure Mediated Drug Delivery: Where Do We Stand?
Current Nanomedicine Functions of MAPR (Membrane-Associated Progesterone Receptor) Family Members As Heme/Steroid-Binding Proteins
Current Protein & Peptide Science Apoptosis Induction by Ultrasound and Microbubble Mediated Drug Delivery and Gene Therapy
Current Molecular Medicine Natural Compounds as Antagonists of Canonical Wnt/β-Catenin Signaling
Current Chemical Biology Concentrations of Cd, Cu, Pb and Zn in Blood Serum of Cancer Patients and Comparison with Healthy Person by Atomic Absorption Spectrometry
Current Analytical Chemistry Synthesis of Purine Derivatives as Scaffolds for a Diversity of Biological Activities
Current Organic Chemistry The Role of Systemic Treatment and Radiotherapy in Malignant Mesothelioma
Current Respiratory Medicine Reviews Modulation of pRb/E2F Functions in the Regulation of Cell Cycle and in Cancer
Current Cancer Drug Targets Acridone-based Antitumor Agents: A Mini-review
Anti-Cancer Agents in Medicinal Chemistry